3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
107
Triple Negative Breast Neoplasms
15
Neoplasm Metastasis
14
Carcinoma, Renal Cell
6
Breast Neoplasms, Male
6
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Breast Diseases
2
Advanced Breast Cancer
2
Unilateral Breast Neoplasms
1
Thrombocytosis
1
Somatostatinoma
1
Skin Diseases
1
Prostatic Neoplasms
1
Primary Non-metastatic Breast Cancer
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
Fulvestrant
2
vistusertib
1
proto-oncogene protein c-fes-fps
1
capivasertib
1
Transurethral Resection of Bladder
1
Hydroxychloroquine
1
Everolimus
1
Estrogens
1
Estradiol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Estrogen Receptor Positive Breast Cancer
×
Everolimus
×
Breast
×
Clear all
NCT02216786
2024-12-02
MANTA
Queen Mary University of London
Phase 2
Completed
333 enrolled